Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy

Sylvain Ladoire; David Enot; Fabrice Andre; Laurence Zitvogel; Guido Kroemer

doi:10.1080/2162402X.2015.1082706

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy

Sylvain Ladoire, David Enot, Fabrice Andre, Laurence Zitvogel, Guido Kroemer

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

Original language	English
Journal	OncoImmunology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1080/2162402X.2015.1082706
Publication status	Published - 1 Feb 2016

Keywords

Breast cancer
HMGB1
Histology
Immunogenic cell death
LC3B
P62
SQSTM1

Access to Document

10.1080/2162402X.2015.1082706

Cite this

@article{cf899dac83ad46f895882c3d9380c2a9,

title = "Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy",

abstract = "It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.",

keywords = "Breast cancer, HMGB1, Histology, Immunogenic cell death, LC3B, P62, SQSTM1",

author = "Sylvain Ladoire and David Enot and Fabrice Andre and Laurence Zitvogel and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2016 Taylor & Francis Group, LLC.",

year = "2016",

month = feb,

day = "1",

doi = "10.1080/2162402X.2015.1082706",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

number = "2",

}

TY - JOUR

T1 - Immunogenic cell death-related biomarkers

T2 - Impact on the survival of breast cancer patients after adjuvant chemotherapy

AU - Ladoire, Sylvain

AU - Enot, David

AU - Andre, Fabrice

AU - Zitvogel, Laurence

AU - Kroemer, Guido

PY - 2016/2/1

Y1 - 2016/2/1

N2 - It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

AB - It is well established that the anticancer immune response determines the success of anthracycline-based adjuvant chemotherapy of breast cancer. This effect is in part due to the capacity of anthracyclines to induce immunogenic cell death (ICD), a cell death modality that is preceded by autophagy and followed by HMGB1 release. Recent data on 1,798 mammary carcinoma specimens indicate that patients harboring neoplastic cells that lack immunohistochemical signs of autophagy or that have lost HMGB1 expression have indeed a poor prognosis.

KW - Breast cancer

KW - HMGB1

KW - Histology

KW - Immunogenic cell death

KW - LC3B

KW - P62

KW - SQSTM1

UR - http://www.scopus.com/inward/record.url?scp=84959449499&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1082706

DO - 10.1080/2162402X.2015.1082706

M3 - Article

AN - SCOPUS:84959449499

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 2

ER -

Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy

Abstract

Keywords

Access to Document

Other files and links

Cite this